دورية أكاديمية
أعرض في EDS

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

التفاصيل البيبلوغرافية
العنوان: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.
المؤلفون: León L; Medical Oncology Department, Complejo Hospitalario Universitario de Santiago, A Coruña, Spain, luis.leon.mateos@sergas.es., García-Figueiras R, Suárez C, Arjonilla A, Puente J, Vargas B, Méndez Vidal MJ, Sebastiá C
المصدر: Targeted oncology [Target Oncol] 2014 Mar; Vol. 9 (1), pp. 9-24. Date of Electronic Publication: 2013 Dec 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Paris : Springer-Verlag France, c2006-
مواضيع طبية MeSH: Practice Guidelines as Topic*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Renal Cell/*diagnosis , Carcinoma, Renal Cell/*drug therapy , Kidney Neoplasms/*diagnosis , Kidney Neoplasms/*drug therapy, Biomarkers, Pharmacological/analysis ; Carcinoma, Renal Cell/pathology ; Clinical Trials as Topic ; Diagnostic Imaging/methods ; Humans ; Kidney Neoplasms/pathology ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Prognosis ; Treatment Outcome
مستخلص: The evaluation of response to treatment is a critical step for determining the effectiveness of oncology drugs. Targeted therapies such as tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors are active drugs in patients with metastatic renal cell carcinoma (mRCC). However, treatment with this type of drugs may not result in significant reductions in tumor size, so standard evaluation criteria based on tumor size, such as Response Evaluation Criteria in Solid Tumors (RECIST), may be inappropriate for evaluating response to treatment in patients with mRCC. In fact, targeted therapies apparently yield low response rates that do not reflect increased disease control they may cause and, consequently, the benefit in terms of time to progression. To improve the clinical and radiological evaluation of response to treatment in patients with mRCC treated with targeted drugs, a group of 32 experts in this field have reviewed different aspects related to this issue and have put together a series of recommendations with the intention of providing guidance to clinicians on this matter.
التعليقات: Erratum in: Target Oncol. 2014 Jun;9(2):181. García-Figueras, Roberto [corrected to García-Figueiras, Roberto].
References: Eur J Cancer. 2006 Oct;42(15):2472-9. (PMID: 16965911)
Radiology. 2010 Aug;256(2):511-8. (PMID: 20551183)
Clin Cancer Res. 2011 Aug 15;17(16):5443-50. (PMID: 21828239)
Radiographics. 2011 Nov-Dec;31(7):2059-91. (PMID: 22084189)
Invest Radiol. 2012 Jan;47(1):2-4. (PMID: 21808202)
AJR Am J Roentgenol. 2012 Nov;199(5):W554-64. (PMID: 23096199)
Magn Reson Imaging Clin N Am. 2011 Feb;19(1):181-209. (PMID: 21129641)
J Clin Oncol. 2012 Sep 20;30(27):3402-7. (PMID: 22891270)
Clin Cancer Res. 2012 Dec 15;18(24):6588-98. (PMID: 23092875)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Nature. 1999 May 20;399(6733):271-5. (PMID: 10353251)
Acta Radiol. 2010 Jun;51(5):581-9. (PMID: 20429759)
AJR Am J Roentgenol. 2007 Aug;189(2):378-85. (PMID: 17646464)
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):747s-752s. (PMID: 17255304)
Cancer. 1981 Jan 1;47(1):207-14. (PMID: 7459811)
Cancer Biol Ther. 2010 Jan;9(1):15-9. (PMID: 20009542)
J Nucl Med. 2010 May;51(5):761-7. (PMID: 20395337)
Bull Cancer. 2000 Dec;87(12):927-34. (PMID: 11174123)
N Engl J Med. 2005 Dec 8;353(23):2477-90. (PMID: 16339096)
Neoplasia. 2009 Feb;11(2):102-25. (PMID: 19186405)
Lancet. 2007 Dec 22;370(9605):2103-11. (PMID: 18156031)
Cancer. 2010 May 15;116(10):2332-42. (PMID: 20225226)
Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. (PMID: 21763969)
Clin Cancer Res. 2011 Sep 15;17(18):6021-8. (PMID: 21742806)
Radiographics. 2008 Mar-Apr;28(2):329-44. (PMID: 18349443)
Eur Radiol. 2012 Jul;22(7):1442-50. (PMID: 22302501)
N Engl J Med. 2007 Jan 11;356(2):185-7. (PMID: 17215538)
Bull Cancer. 2007 Feb;94(2):171-7. (PMID: 17337386)
Eur Radiol. 2012 Jul;22(7):1451-64. (PMID: 22562143)
J Clin Oncol. 1999 Aug;17(8):2530-40. (PMID: 10561319)
Eur Radiol. 2012 Jul;22(7):1430-41. (PMID: 22367468)
J Urol. 2003 Aug;170(2 Pt 1):588-92. (PMID: 12853836)
J Clin Oncol. 2009 Dec 1;27(34):5794-9. (PMID: 19826129)
Ann Oncol. 2010 May;21(5):936-41. (PMID: 19889607)
AJR Am J Roentgenol. 2012 Jun;198(6):1266-76. (PMID: 22623538)
Clin Radiol. 2011 Nov;66(11):1055-9. (PMID: 21843882)
Theranostics. 2011 Jan 17;1:48-57. (PMID: 21547152)
Abdom Imaging. 2010 Oct;35(5):622-8. (PMID: 19763683)
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9. (PMID: 8855223)
Lancet. 2000 Jul 29;356(9227):373-8. (PMID: 10972369)
AJR Am J Roentgenol. 2012 Apr;198(4):737-45. (PMID: 22451534)
Cancer Biother Radiopharm. 2009 Feb;24(1):137-44. (PMID: 19243256)
Br J Cancer. 2010 Mar 2;102(5):803-9. (PMID: 20145618)
Theranostics. 2012;2(5):502-15. (PMID: 22737188)
Cancer. 2003 Oct 15;98(8):1611-9. (PMID: 14534876)
J Nucl Med. 2011 Jul;52(7):1048-55. (PMID: 21680694)
J Clin Oncol. 2008 Oct 1;26(28):4572-8. (PMID: 18824708)
Cancer Biol Ther. 2008 Apr;7(4):496-501. (PMID: 18219225)
Eur Urol. 2010 Aug;58(2):307-10. (PMID: 20347211)
J Clin Oncol. 2008 Nov 20;26(33):5422-8. (PMID: 18936475)
World J Urol. 2014 Feb;32(1):31-8. (PMID: 23404195)
Bioorg Med Chem Lett. 2005 Oct 1;15(19):4380-4. (PMID: 16019210)
Nucl Med Commun. 2009 Jul;30(7):519-24. (PMID: 19522059)
Eur J Cancer. 2012 Jul;48(10):1512-8. (PMID: 22342553)
Cancer Imaging. 2012 Jan 12;11:259-65. (PMID: 22245974)
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437)
Lancet. 2008 Aug 9;372(9637):449-56. (PMID: 18653228)
Bull Cancer. 2012 Apr 1;99(4):E34-42. (PMID: 22455955)
N Engl J Med. 2007 May 31;356(22):2271-81. (PMID: 17538086)
Lancet Oncol. 2007 Nov;8(11):975-84. (PMID: 17959415)
Eur Radiol. 2012 Jul;22(7):1465-78. (PMID: 22476502)
Nat Genet. 1994 May;7(1):85-90. (PMID: 7915601)
Ann Intern Med. 1996 Oct 1;125(7):605-13. (PMID: 8815760)
Am J Cancer Res. 2011;1(2):240-254. (PMID: 21969126)
Eur Radiol. 2001;11(12):2504-9. (PMID: 11734949)
AJR Am J Roentgenol. 2013 Jan;200(1):8-19. (PMID: 23255736)
J Nucl Med. 2008 Jan;49(1):22-9. (PMID: 18077538)
AJR Am J Roentgenol. 2010 Jan;194(1):5-14. (PMID: 20028898)
AJR Am J Roentgenol. 2010 Jan;194(1):157-65. (PMID: 20028918)
Eur Urol. 2011 May;59(5):856-62. (PMID: 21306819)
Hematol Oncol Clin North Am. 2011 Aug;25(4):667-86. (PMID: 21763962)
AJR Am J Roentgenol. 2010 Jun;194(6):1470-8. (PMID: 20489085)
Radiology. 2011 Aug;260(2):581-90. (PMID: 21555352)
Target Oncol. 2010 Jun;5(2):95-112. (PMID: 20625845)
Ann Oncol. 2012 May;23(5):1293-1300. (PMID: 22015450)
Curr Urol Rep. 2012 Feb;13(1):70-81. (PMID: 22143974)
سلسلة جزيئية: ClinicalTrials.gov NCT00930033; NCT01099423
المشرفين على المادة: 0 (Biomarkers, Pharmacological)
تواريخ الأحداث: Date Created: 20131217 Date Completed: 20150110 Latest Revision: 20211021
رمز التحديث: 20221213
DOI: 10.1007/s11523-013-0304-7
PMID: 24338498
قاعدة البيانات: MEDLINE
الوصف
تدمد:1776-260X
DOI:10.1007/s11523-013-0304-7